Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

NCT02647944 on ClinicalTrials.gov · last registry update 2017-10-27

A small phase 2 — 40 participants, against a typical 110. The sponsor logged completion for 30 December 2016. Primary outcome, as filed: Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 40
Started: 2015-12-18
Primary completion: 2016-12-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.